EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection

Daniel C Bailey iD, Salvador Castañeda-Barba iD, Katie E Barry, Puthayalai Treerat iD, Matthew A Crawford iD, Molly A Hughes iD, Amy J Mathers iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01651-25 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Daniel C Bailey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virgini…. Hauptthemen laut MEDLINE: Serratia marcescens, beta-Lactamase Inhibitors, Serratia Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Klebsiella pneumoniae carbapenemases (KPCs) are a family of serine β-lactamases that confer broad antibiotic resistance by hydrolyzing virtually all β-lactam (BL) agents. Contemporary β-lactamase inhibitors (BLIs) such as avibactam were developed to neutralize the activity of KPCs and other clinically important carbapenemases. Ceftazidime-avibactam (CZA), a BL/BLI combination in which the cephalosporin ceftazidime is protected from KPC-mediated hydrolysis, demonstrated improved outcomes in early clinical use. However, CZA-resistant isolates soon emerged. Herein, we describe a challenging clinical case in which high-level resistance to CZA evolved during therapy for a complicated infection caused by carbapenem-resistant Serratia marcescens harboring bla KPC-2 . Whole-genome sequencing, analysis of antibiotic resistance genes, and phenotypic susceptibility assays of serial S. marcescens isolates revealed that resistance arose via a 45-nucleotide in-frame duplication within bla KPC-2 , yielding KPC variant 44 ( bla KPC-44 ). Notably, the evolution of bla KPC-44 not only conferred resistance to CZA but also marked cross-resistance to meropenem-vaborbactam and imipenem-relebactam while remaining susceptible to cefiderocol. To our knowledge, this report represents the first description of bla KPC-44 emerging outside of K. pneumoniae and among the few documenting a CZA-resistance-conferring KPC variant emerging in a non -K . pneumoniae Enterobacterales species. Ultimately, the evolved strain persisted despite therapy throughout a fatal clinical course, underscoring the potential for CZA selective pressure to drive treatment-emergent resistance to multiple contemporary BL/BLI agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serratia marcescensbeta-Lactamase InhibitorsSerratia InfectionsAnti-Bacterial Agentsbeta-LactamasesAzabicyclo CompoundsMicrobial Sensitivity TestsDrug CombinationsHumansCeftazidimeBacterial ProteinsKlebsiella pneumoniaeDrug Resistance, Multiple, BacterialCefiderocolThird Generation CephalosporinsBoronic AcidsMeropenembeta-Lactams

Stichwörter der Autor:innen

KPC-44Klebsiella pneumoniae carbapenemaseSerratia marcescensallele variationavibactam resistancecarbapenem resistancecarbapenem-resistant Enterobacteralesceftazidime-avibactammultidrug resistancerelebactam resistancevaborbactam resistance

Substanzen

beta-Lactamase InhibitorsAzabicyclo CompoundsAnti-Bacterial Agentsbeta-LactamasesDrug Combinationsavibactam, ceftazidime drug combinationCeftazidimeBacterial ProteinsCefiderocolThird Generation Cephalosporins

Autor:innen und Institutionen

  • Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Clinical Microbiology Laboratory, University of Virginia Health System, Charlottesville, Virginia, USA.
  • Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

ORCID-Profile: Daniel C Bailey, Salvador Castañeda-Barba, Puthayalai Treerat, Matthew A Crawford, Molly A Hughes, Amy J Mathers

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Bailey, D. C., Castañeda-Barba, S., Barry, K. E., Treerat, P., Crawford, M. A., Hughes, M. A., & Mathers, A. J. (2026). In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01651-25

Vancouver

Bailey DC, Castañeda-Barba S, Barry KE, Treerat P, Crawford MA, Hughes MA, et al. In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01651-25

BibTeX
@article{Bailey2026,
  author = {Bailey, Daniel C and Castañeda-Barba, Salvador and Barry, Katie E and Treerat, Puthayalai and Crawford, Matthew A and Hughes, Molly A and Mathers, Amy J},
  title = {In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01651-25}
}
Kostenlos starten →